• 대한핵의학회지
• /
• 제13권1_2호
• /
• pp.61-71
• /
• 1979

The authors investigated the incidence of antithyroglobulin antibodies and antibodies and antimicrosomal antibodies measured by tanned red cell hemagglutination method in subjects suffering from various thyroid disorders. 1) In 15 normal patients, neither suffering from any thyroid diseases nor from any other autoimmune disorders, the anti thyroglobulin antibodies were all negative, but the antimicrosomal antibody was positive only in one patient (6.7%). 2) The antithyroglobulin antibodies were positive in 31.5% (34 patients) of 108 patients with various thyroid diseases, and the antimicrosomal antibodies were positive in 37.0% (40 patients). 3) of the 25 patients with Graves' diseases, 7 patients (28.0%) showed positive for the antithyroglobulin antibodies, and 9(36.0%) for the antimicrosomal antibodies. There was no definite differences in clinical and thyroid functions between the groups with positive and negative results. 4) Both antibodies were positive in 16(88.9%) and 17(94.4%) patients respectively among 18 patients with Hashimoto's thyroiditis, all of them were diagnosed histologically. 5) Three out of 35 patients with thyroid adenoma showed positive antibodies, and 3 of 16 patients with thyroid carcinoma revealed positive antibodies. 6) TRCH antibodies demonstrated negative results in 2 patients with subacute thyroiditis, but positive in one patient with idiopathic primary myxedema. 7) The number of patients with high titers ($>1:80^2$) was 16 for antithyroglobulin antibody and 62.5%(10 patients) of which was Hashimoto's thyroiditis. Thirteen(65.0) of 20 patients with high titers($>1:80^2$) for antimicrosomal antibody was Hashimoto's thyroiditis. TRCH test is a simple, sensitive method, and has high reliablity and reproducibility. The incidences and titers of antihyroglobulin antibody and antimicrosomal antibody are especially high in Hashimoto's thyroiditis.

• IMMUNE NETWORK
• /
• 제3권2호
• /
• pp.118-125
• /
• 2003

Background: Disialoganglioside GD2 is a tumor-associated antigen that is overexpressed on tumor cells of neuroectodermal origin, such as melanoma and neuroblastoma. Anti-idiotypic antibodies that mimic GD2 may induce more effective immune responses than GD2 antigen itself, because they are protein antigens and are known to be able to break immune tolerance. In this study, to explore the potential of anti-idiotypic antibodies as tumor vaccines, the ability of anti-idiotypic antibodies (Ab2) to induce anti-anti-idiotypic antibodies (Ab3) that bind to the original antigen GD2 was investigated. Methods: Six monoclonal anti-idiotypic antibodies (1A8, 1G5, 2B6, 3A4, 3D6, 3H9) to monoclonal antibody M2058, which is a monoclonal antibody to GD2, were produced in mice. Three (1A8, 3A4, 3H9) of them were selected based on their ability to inhibit the binding of Ab1 to D142.34 (murine melanoma cell expressing GD2). These 3 different Ab2 were injected into rabbits, and rabbit Ab3 induced by each of them were characterized. Results: Ab3-containing sera from two rabbits immunized with 1A8, 3A4, or 3H9 bound significantly (P<0.05) to D142.34 but not to B78.96 (GD2-negative cell), and bound significantly (P<0.05) to isolated GD2 but not to GD1a. Ab3-containing sera from two rabbits immunized with 3A4 or 3H9 inhibited significantly (P<0.05) the binding of Ab1 M2058 to D142.34, and inhibited significantly (P<0.05) the binding of Ab1 M2058 to the Ab2. Conclusion: These results suggest that anti-idiotypic antibodies 3A4 and 3H9 have a potential to be used as vaccines against tumors expressing GD2 by inducing GD2-specific antibodies (Ab3).

• 한국식품과학회지
• /
• 제32권6호
• /
• pp.1221-1226
• /
• 2000

대두단백질의 분석을 위한 효소면역측정법을 개발하고자 특이항체를 생산하고 그 항체의 특성을 비교하였다. 분리대두단백(ISP), ISP를 SDS와 urea의 첨가하에 열처리한 것(ISP(SU)), 11S 글로불린의 acidic subunit(AS)를 각기 면역하여 다클론 항체를 생산하였다. 간접 경합 효소면역측정법(ciELISA)을 실시하여 처리를 달리한 대두단백질에 대한 이들 항체의 반응성을 조사하였여 $IC_{50}$으로 나타내었다. 항AS 항체의 경우 $IC_{50}$값이 ISP, ISP(SU), ISP를 2-ME로 처리한 ISP(ME), crude 11S에 대하여 각각 20, 2, 2.5, $200\;{\mu}g/mL$로 나타났다. 또한, 항ISP(SU) 항체의 경우 같은 항원에 대해서 100, 5, 4, $220\;{\mu}g/mL$였으며 항ISP 항체의 경우는 각각 20, 30, 36, $1000\;{\mu}g/mL$로 나타났다. 이로서 생산된 3가지 항체 중에서 항AS 항체가 대두단백질에 대한 반응성이 가장 우수하여 ELISA분석법 개발에 적합하였다.

• Journal of Veterinary Science
• /
• 제22권3호
• /
• pp.38.1-38.17
• /
• 2021

Background: The feline viral rhinotracheitis, calicivirus, and panleukopenia (FVRCP) vaccine, prepared from viruses grown in the Crandell-Rees feline kidney cell line, can induce antibodies to cross-react with feline kidney tissues. Objectives: This study surveyed the prevalence of autoantibodies to feline kidney tissues and their association with the frequency of FVRCP vaccination. Methods: Serum samples and kidneys were collected from 156 live and 26 cadaveric cats. Antibodies that bind to kidney tissues and antibodies to the FVRCP antigen were determined by enzyme-linked immunosorbent assay (ELISA), and kidney-bound antibody patterns were investigated by examining immunofluorescence. Proteins recognized by antibodies were identified by Western blot analysis. Results: The prevalences of autoantibodies that bind to kidney tissues in cats were 41% and 13% by ELISA and immunofluorescence, respectively. Kidney-bound antibodies were observed at interstitial cells, apical border, and cytoplasm of proximal and distal tubules; the antibodies were bound to proteins with molecular weights of 40, 47, 38, and 20 kDa. There was no direct link between vaccination and anti-kidney antibodies, but positive antibodies to kidney tissues were significantly associated with the anti-FVRCP antibody. The odds ratio or association in finding the autoantibody in cats with the antibody to FVRCP was 2.8 times higher than that in cats without the antibody to FVRCP. Conclusions: These preliminary results demonstrate an association between anti-FVRCP and anti-cat kidney tissues. However, an increase in the risk of inducing kidney-bound antibodies by repeat vaccinations could not be shown directly. It will be interesting to expand the sample size and follow-up on whether these autoantibodies can lead to kidney function impairment.

• 한국생활과학회지
• /
• 제5권1호
• /
• pp.75-80
• /
• 1996

The immunogenecity of low molecular weight ($MW{\le}30,000$) immunogens in laying hens was investigated. Immunogens were insulin derivatives and ${\beta}$-lactoglobulin(${\beta}-Lg$). Insulin derivatives were reduced- carboxymethylated(RCM) insulin, and RCM-A and RCM-B chain of insulin. The yolk antibodies against RCM-A chain of insulin appeared after the first immunization. The yolk antibodies against RCM-B chain of insulin were elicited 5 weeks after the third booster injection. Although the anti-RCM-B chain yolk antibodies recognized native insulin, the anti-RCM-A chain yolk antibodies didn't native insulin. The anti-RCM insulin yolk antibodies were induced after the second booster injection and showed cross-reactivities with native insulin. On the other hand, ${\beta}-Lg$ showed stronger immunogenecity than insulin derivatives. The $anti-{\beta}-Lg$ yolk antibodies were produced after the second booster injection and the peak titer was reached 3 weeks after the third booster injection.

• BMB Reports
• /
• 제34권5호
• /
• pp.452-456
• /
• 2001

Surface plasmon resonance has been used for a biospecific interaction analysis between two macromolecules in real time. Determination of an antibody that is capable of specifically interacting with the native form of antigen is very useful for many biological and medical applications. Twenty monoclonal antibodies against the $\alpha$ subunit of E. coli DNA polymerase III were screened for specifically recognizing the native form of protein using surface plasmon resonance. Only four monoclonal antibodies among them specifically recognized the native $\alpha$ protein, although all of the antibodies were able to specifically interact with the denatured $\alpha$ subunit. These antibodies failed to interfere with the interaction between the $\tau$ and $\alpha$ subunits that were required for dimerization of the two polymerases at the DNA replication fork. This real-time analysis using surface plasmon resonance provides an easy method to screen antibodies that are capable of binding to the native form of the antigen molecule and determine the biological interaction between the two molecules.

• 대한핵의학회지
• /
• 제18권1호
• /
• pp.19-24
• /
• 1984

Clinical measurement of thyroid autoantibodies in sera of some thyroid disorders have been widely applied since about twenty years ago. We investigated the incidence and titers of both anti microsomal and antithyroglobulin antibodies in forty eight cases with controls and one hundred and thirty three patients with some form of thyroid disorders. The results were as follows; 1) In controls, antimicrosomal antibodies were positive in 2% but anti thyroglobulin antibodies were all negative. 2) In a series of one hundred and thirty three patients with thyroid disease, anti microsomal antibodies were positive in 44% but antithyroglobulin antibodies were positive in only 15%. 3) The rate disclosing the positive results of antimicrosomal antibodies were 71 % in Hashmoto's disease, 60% in Graves' disease, and 38% in primary hypothroidism, respectively. On the other hand, the positive results of antithyroglobulin antibodies showed 21 % in Graves' disease, 19% in primary hypothyroidism, and 18% in Hashmoto's disease, respectively. Though there were relatively high rate of both antimicrosomal and anti thyroglobulin antibodies in patients with nodular goiter, they were only seven cases in our series. 4) The rate with the extremely high titers of antimicrosomal and antithyroglobulin antibodies$(>1:160^2)$ was 83% and 67% in Hashmoto's disease, 50% and 67% in primary hypothyroidism, and 41% and 18% in Graves' disease. Accordingly, the thyroid autoantibodies were commonly found higher positive rate in patients with Hashmoto's disease, primary hypothyroidism, and Graves' disease. Among these disorders, the extremely high positive rate of the thyroid autoantibodies was found in patients with Hashmoto's disease.

• BMB Reports
• /
• 제30권6호
• /
• pp.390-396
• /
• 1997

A sandwich-type enzyme-linked immunosorbent assay (ELISA) for the quantification of human apolipoprotein A-I (apoA-I) was developed using monoclonal antibodies. For this assay, we used three monoclonal antibodies to trap and detect apo A-I. HDAI16 and HDA15 monoclonal antibodies were used for trapping apoA-I and HDAI8 monoclonal antibody was for detecting apoA-I. These three monoclonal antibodies were produced by immunizing mice with high density lipoprotein (HDL) isolated from human plasma. By immunoblot analysis, these three monoclonal antibodies were specific to apoA-I and showed no cross-reactivities with other plasma proteins. The results of competition assays for epitope cross-reactivity test also verified that these monoclonal antibodies identified separate and distinct epitopes on HDL and apoA-I. Affinity constants of monoclonal antibodies were measured by ELISA. Their association constants ranged from $10^7$ to $10^8$ $M^{-1}$. For this assay, pure apoA-I was isolated by affinity chromatography using monoclonal antibodies. In this sandwich assay, the amount of HRP-labeled HDAI8 bound to apoA-I trapped by HDAI16 and HDAI5 was proportional to apoA-I concentration in the range of 0 to 500ng/ml. ApoA-I concentration in plasma was calculated from the linear regression equation of standard curve. The precision and reliability of the assays are reflected in the low intra-and interassay coefficients of variation that averaged 3.25% and 4.30%, respectively. This assay is sensitive, simple, reproducible, convenient in incubation interval, and does not use radioisotope: thus it can be widely applied in clinical laboratories.

• 한국동물위생학회지
• /
• 제32권2호
• /
• pp.131-137
• /
• 2009

This study was conducted to determine the prevalence of antibodies to Toxoplasma gondii (TG) in cattle and pigs reared in eastern areas of Gyeongbuk province by ELISA. Among 368 sera collected from 119 cattle farms, 76 (20.7%) sera from 34 (28.6%) farms had antibodies to TG. Fifty (27.2%) out of 184 cattle in Uljin-gun and 26 (14.1%) out of 184 cattle in Yeongdeok-gun were positive. Pyeonghae (50.0%) in Uljin-gun and Dalsan (33.3%) in Yeongdeok-gun had the highest TG antibodies in cattle compared to other areas. Prevalence of TG antibodies in cattle was increased with age. Among 368 sera collected from 43 pig farms, 62 (16.8%) sera from 16 (37.2%) farms had antibodies to TG. Forty (21.7%) out of 184 pigs in Uljin-gun and 22 (12.0%) out of 184 pigs in Yeongdeok-gun were positive. Uljin and Puk (40.0%) in Uljin-gun and Yeonghae (33.3%) in Yeongdeok-gun had the highest TG antibodies in pigs compared to other areas. Prevalence of TG antibodies in sows was higher than that in fattening pigs. Seasonally, prevalence of TG antibodies in pigs was highest in summer (23.4%) and lowest in winter (12.5%). Based on these observations, data indicate that infection by the protozoan parasite TG is widely prevalent in cattle and pigs reared in eastern areas of Gyeongbuk province.

• 한국미생물·생명공학회지
• /
• 제51권3호
• /
• pp.223-242
• /
• 2023

In contrast to chemical medicines, biopharmaceuticals exhibit reduced side effects and enhanced therapeutic efficacy. Antibody therapies have significantly advanced since the first monoclonal antibody's approval in 1986, now dominating the pharmaceutical market with seven out of the top 10 biopharmaceuticals. The bispecific antibody has a distinct capability to bind to two antigens simultaneously, unlike conventional monoclonal antibodies that target just one antigen. The notion of bispecific antibodies was initially introduced in 1960, and by 1997, the first symmetrical form of bispecific antibody was successfully produced. Subsequently, extensive research has been conducted on bispecific antibodies, leading to a significant milestone in 2014 when blinatumomab became the first FDA-approved drug to treat acute lymphocytic leukemia. Despite having a relatively shorter history compared to monoclonal antibodies, bispecific antibodies have proven their potential by targeting two antigens simultaneously, thereby rendering them highly effective as anti-cancer drugs. As of 2023, there are a total of 11 globally approved bispecific antibodies, with six of them receiving approval from FDA. In light of the rapidly expanding market for bispecific antibodies, this review article comprehensively explores the attributes, historical background, applications, and market status of bispecific antibodies. Additionally, it sheds light on the present trends in bispecific antibody development, drawing insights from 96 research articles and 105 clinical studies. Excitingly, we anticipate further progress in the development of bispecific antibodies and clinical trials on a global scale, with the aspiration of utilizing them not only in cancer treatment but also for addressing diverse medical conditions.